Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors (PAVO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT05169437

Recruitment Status : Recruiting

First Posted : December 27, 2021

Last Update Posted : May 6, 2023

See Contacts and Locations

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborator:

GlaxoSmithKline

Information provided by (Responsible Party):

Tempus Labs

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	June 1, 2024
Estimated Study Completion Date :	July 1, 2025

To Top